BioSpace News Archive

According to Transparency Market Research’s latest research report on the global bone graft substitutes market for the historical year, base year, and the forecast period, rise in prevalence of bone and joint disorders, technological advancements, increase in government initiatives for joint replacement surgeries, and surge in the number of healthcare facilities are projected to drive the global bone graft substitutes market in the near future.

The conventional low-priced mainstay drugs for the treatment of malaria, sulphadoxine-pyrimethamine and chloroquine, are witnessing a decline in sales, as they are becoming comparatively ineffective.

According to Transparency Market Research’s latest report on the global mobile imaging services market for the historical period 2017–2018 and forecast period 2019–2027, rise in demand for vehicle bound mobile imaging units due to their numerous advantages over fixed imaging equipment, and awareness programs by governments and NGOs are projected to drive the global mobile imaging services market during the forecast period.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Transparency Market Research has published a new report titled, ‘Oligonucleotide Synthesis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Orthopedic braces & supports are medical devices equipped to address musculoskeletal disorders.

Verona Pharma plc announces its development partner, Nuance Pharma, has received clearance from the Center of Drug Evaluation for its Investigational New Drug application to conduct both Phase 1 and Phase 3 studies with ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease in mainland China.

IMPACT Therapeutics announced that the US Food and Drug Administration has granted Orphan-Drug Designation to our fixed-dose combination capsule of Senaparib and temozolomide for the treatment of adult patients with small cell lung cancer.

Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce it has secured a promising new customer in the Mexican dairy industry.

Axsome Therapeutics, Inc. announced that the FDA has approved AUVELITY™ extended-release tablets for the treatment of major depressive disorder in adults.

Intercept Pharmaceuticals, Inc. announced today that it has entered into privately negotiated agreements to repurchase $327.9 million of its secured convertible debt using a combination of cash and equity.